Gain a thorough understanding of miR function
Permanently knockdown miRs with SBI’s miRZip™ anti-miRNA Expression Lentivectors. Leveraging SBI’s powerful and well-regarded third-generation lentivector technology, each of our miRZip lentivectors expresses a short hairpin RNA (shRNA) that, after processing, preferentially produces an anti-sense miRNA. The hairpin is rationally designed to be asymmetric, ensuring that the sense strand does not contain the endogenous miRNA sequence and enabling accumulation of the anti-miRNA. The result is robust derepression of the transcripts targeted by the microRNA being “zipped,” and elevation of the corresponding protein levels.
Study miRs with SBI’s powerful miRZip technology:
- Stable and permanent anti-microRNA expression from a constitutive H1 promoter
- Rationally designed, asymmetric hairpins optimized for anti-sense microRNA production
- Efficient suppression of specific endogenous microRNAs
- Reliable delivery to dividing or non-dividing cells
- Selection/sorting for transfected/transduced cells with either copGFP or puromycin
Conduct high-throughput phenotypic screens with our pool of pre-packaged lentiviral particles containing our entire miRZip collection (Cat.# MZIPPLVA-1).
See SBI’s mirZip technology in action
miRZip constructs express high levels of anti-microRNAs
Figure 1. miRZip constructs express high levels of anti-microRNAs. miRZip constructs were transfected into HEK293 cells, total RNA isolated, and miRZip levels measured using SBI’s QuantiMir Assay (Cat.# RA420A-1). Compared to QuantiMir assays performed on RNA isolated from non-transfected cells, the miRZip-transfected cells delivered high expression levels of the specific miRZip anti-miRNAs.
Efficient modulation of target protein levels by SBI’s Lenti-miR and miRZip technologies
Figure 2. Target protein levels are efficiently modulated by SBI’s Lenti-miR-29a and miRZip-29a microRNA constructs.
miRZip technology is effective in a functional assay
Figure 3. miRZip-21 and miRZip-145 exhibit anti-oncogenic and oncogenic activity, respectively, in a cell invasion assay using MDA-MB-231 breast cancer cells. (Top panel) miR-21 is an oncogenic miRNA and miR-145 is a tumor suppressing miRNA. Transduction of miRZip-21 (the anti-miR21 lentiviral construct) and miRZip-145 (the anti-miR145 lentiviral construct), inhibited the respective miRs, resulting in a lower percentage of invading cells in miRZip-21-transduced cells and a higher percentage of invading cells in miRZip-145-transduced cells. (Bottom panel) Additionally, the miRZip-145 lentivirus inhibited endogenous miR-145 and elevated protein expression levels of the miR-145 target oncogene c-Myc.